Stability of Alteplase for Ultrasound-Facilitated Catheter-Directed Thrombolysis
Posted by Adam Awdish on
Human tPA ELISA Kit from Innovative Research was used in the following study:
Stability of Alteplase for Ultrasound-Facilitated Catheter-Directed Thrombolysis
John Fanikos, Kathleen Marquis, Leo Buckley, Lena K. Tran, Kevin McLaughlin, Abby Jane Golash, Umberto Campia, Gregory Piazza, Jean M. Connors, Samuel Z. Goldhaber
Blood Advances
December 8, 2021
Ultrasound-facilitated catheter-directed thrombolysis (USCDT) is a form of treatment for pulmonary embolism that may minimize the effects of major bleeding complications during treatment. USCDT typically uses low-dose alteplase over the course of up to 8 hours, as major bleeding complications usually result from the administration of high doses of alteplase through a systemic vein, however some studies suggest that it is safe to administer alteplase in normal clinical conditions over just 2 to 6 hours.
Unfortunately, there isn’t much data to support these studies, and thus it remains unclear whether the alteplase will remain stable and effective when administered in this way. To investigate these claims, researchers in this study used a Human tPA ELISA Kit from Innovative Research to quantify alteplase concentrations both with and without ultrasound.
Related products available from Innovative Research also include: